In January 2025, the FDA approved suzetrigine (Journavx), the first entirely new class of non-opioid pain medication in over two decades. The drug blocks sodium channels to relieve acute pain without the addiction risks associated with opioids.
The U.S. Food and Drug Administration approved suzetrigine, marketed as Journavx, in January 2025, marking a historic milestone in pain management. It is the first entirely new class of non-opioid pain medication approved in more than 20 years. The drug works by selectively blocking NaV1.8 sodium channels in peripheral nerves, which are involved in sending pain signals to the brain, without affecting the central nervous system pathways that make opioids so addictive.
The approval comes at a critical time: the opioid epidemic has claimed over 500,000 lives in the United States alone since 1999. In clinical trials, suzetrigine proved effective for moderate-to-severe acute pain following dental surgery and abdominoplasty. Patients reported significant pain relief comparable to existing options but without the euphoric effects that lead to dependence. Pharmaceutical experts say this approval could open the floodgates for a new generation of non-addictive painkillers, with several similar drugs already in development pipelines worldwide.
“S.”
How did this story make you feel?
